Russian CRO Atlant Clinical continues to grow 'despite certain political and economic challenges’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/hansslegers)
(Image: Getty/hansslegers)
The Russia-based CRO Atlant Clinical has received certification in the organization and management of clinical trials – demand for which continues to increase despite political and economic challenges.

Atlant Clinical has received ISO 9001:2015​ certification in the organization and management of clinical trials. According to the company, it is the first and only contract research organization (CRO) in Russia to be granted the certification after successfully passing the Bureau Veritas audit.

The company received ISO 9001:2008​ certification in 2015. 

Marietta Sarkisyan, business development and marketing manager, Atlant Clinical, said the certification highlights the “quality and compliance of all operations of Atlant Clinical”​ and “certifies that all work is done in accordance with the best international practices.” 

The CRO operates not only in Russia, but also in Eastern and Western Europe, the US, Baltics, and ex-USSR markets, Sarkisyan said. “We do not see decline of demand for our services in Russia as we have been on the market for over 10 years and have excellent reputation with both our sponsors and other pharmaceutical and biotech companies,”​ she told us.

Atlant’s repeat business rate is well above 80%, Sarkisyan explained, “so our Russian turnover continues to grow despite certain political and economic challenges.”

“We constantly work on increasing our European and North American business, so share of Russian projects in our portfolio gradually declines,”​ she added.

As the company develops, Sarkisyan said it is able to take on more challenging and comprehensive international projects. “We now have more trials that cover 10+ countries,” ​she added, “and we see more projects from global pharmaceutical and biotech firms.”

These projects are larger and drive the company’s revenue numbers up, explained Sarkisyan. “Finally, we have long-term contracts with some of our clients, where we provide ongoing clinical and other professional support.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more